• Explore /
  • Poster
  • / Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

Abstract Video & Slides Poster

Authors

David S. Hong

David S. Hong

University of Texas MD Anderson Cancer Center, Houston, TX

David S. Hong , Lin Shen , Cornelis Martinus van Tilburg , Daniel Shao-Weng Tan , Shivaani Kummar , Jessica Jiyeong Lin , Francois P. Doz , Raymond S. McDermott , Catherine M. Albert , Jordan Berlin , Stefan S. Bielack , Ulrik Niels Lassen , Makoto Tahara , Ricarda Norenberg , Anna Shurshalina , Marc Mardoche Fellous , Hendrik Nogai , Rui-hua Xu , Theodore Willis Laetsch , Alexander E. Drilon

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT02576431, NCT02122913, NCT02637687

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3108)

DOI

10.1200/JCO.2021.39.15_suppl.3108

Abstract #

3108

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Alexander E. Drilon

First Author: David S. Hong

First Author: Maria E. Cabanillas

First Author: Leo Mascarenhas